The addition of irinotecan to an epidermal growth factor receptor (EGFR) antibody has previously been shown to improve tumor response rate and time to progression but not overall survival (OS) for refractory metastatic colorectal cancer (mCRC). We assessed the "real-world" effectiveness and toxicity of the combination versus monotherapy. In Ontario, Canada, universal public funding is available for either cetuximab plus irinotecan (Cmab 1 I) combination therapy or panitumumab (Pmab) monotherapy, only in patients with refractory nonmutated RAS mCRC. All patients diagnosed before December 2012 and treated with an EGFR antibody for mCRC were identified from the Ontario drug database and linked to the Ontario Cancer Registry and other administrative databases to ascertain baseline characteristics, health services utilization, and outcomes. Multivariable Cox and logistic models were constructed to compare the time to treatment discontinuation (TTD), OS, emergency department (ED) or hospital visits between Cmab 1 I and Pmab. Observable confounders were adjusted for using propensity score methods. One thousand and eighty-one patients were identified (Cmab 1 I: 278, Pmab: 803). Patients receiving Cmab 1 I were younger (mean age 61 vs 64 years) and had a longer duration of prior irinotecan treatment. The use of Cmab 1 I as compared to Pmab alone was associated with a prolonged TTD [median: 3.8 months vs 2.8 months] and an improved OS [median: 8.8 months vs. 5.9 months] with an adjusted HR of 0.62 [95% CI 0.53-0.73, p < 0.001]. Both treatment regimens afforded similar 14-day mortality and incidence of ED or hospital visits. The findings for patients over and below the age of 65 were similar.
In an era of personalized medicine, the epidermal growth factor receptor (EGFR) has served as a molecular therapeutic target in metastatic colorectal cancer (mCRC).
1,2 5-fluorouracil-based chemotherapy remains the backbone of first and second line systemic treatment, but in the refractory setting, only the 50% of patients whose tumors lack a mutation in the RAS oncogene may benefit from EGFR-directed antibody therapy. 3 In the remaining 50% of cases, tumors harbor a RAS mutation, which renders EGFR-directed antibodies ineffective. [4] [5] [6] Although cetuximab (Cmab) and panitumumab (Pmab) both have established utility in RAS wild-type refractory mCRC, [5] [6] [7] the optimal use of these agents either alone or in combination with chemotherapy is still unclear. In the BOND study, the addition of irinotecan (I) to Cmab improved tumor response rate and time to progression but not overall survival (OS) in patients with refractory mCRC. 8 However, due to the period in which the study was conducted, the RAS status of trial participants was unknown and cross-over was allowed, possibly limiting the detection of an OS benefit in this trial.
In Ontario, the most populous province in Canada, universal public funding has been available for either Cmab 1 I combination therapy or Pmab alone in patients with refractory KRAS exon 2 wild-type mCRC since 2009. Cmab is not funded as monotherapy and, similarly, Pmab is not funded in combination with chemotherapy. No prospective trials have compared these two funded options, and hence, we assessed the effectiveness and toxicity of combination versus monotherapy in a "real world" cohort, including a preplanned subanalysis in older patients who are often under-represented in randomized trials.
Materials and Methods
All patients diagnosed up to December 2012 and treated with an EGFR antibody for refractory mCRC were identified from the New Drug Funding Program database from Cancer Care Ontario, which captures all the publicly funded Cmab and Pmab in Ontario, the most populous province in Canada. Patients were considered to have refractory mCRC if they had stage IV disease and were refractive and/or intolerant to first and second line irinotecan-and oxaliplatin-based chemotherapy. Patient data were linked to the Ontario Cancer Registry and other administrative databases to ascertain baseline characteristics, health services utilization, and outcomes (Supporting Information I).
The primary outcome was OS, defined as time from initiating an EGRF antibody to the time of death due to any cause. The key secondary outcomes were emergency department (ED) and hospital visits, as defined by the incidence from treatment initiation to 30 days after the last dose of an EGFR antibody. Other secondary outcomes included mortality within 14 days and mortality within 30 days of the last dose of an EGFR antibody therapy. Time to treatment discontinuation (TTD) was also assessed and defined as time from initiating an EGFR antibody to the time of either discontinuation of therapy or death on treatment. Data were censored if patients were alive on the same therapy at last available follow-up visit.
Categorical variables are presented as a percentage of nonmissing cases and continuous variables are described as either a mean (std) or median with an interquartile range (IQR). Treatment differences between the two treatment groups were compared using Chi-squared tests for categorical variables and Wilcoxon tests for continuous variables. Kaplan-Meier analyses were performed for the time to event endpoints and compared using the log-rank test. We also used multivariable Cox regression models for time to event endpoints, whereas multivariable logistic models were employed for binary outcomes. Finally, the effect of age at treatment (<65 versus 65 years) on OS, TTD, and toxicity endpoints were also examined.
To account for treatment selection bias and confounding, we used a complete case propensity score stratification regression analysis. Covariates used to construct propensity score included age (in years) at treatment, gender (male versus female), type of cancer (colon versus rectal versus colon and rectal), index year of diagnosis (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) , stage at presentation (stage IV versus other), time from initial diagnosis of colorectal cancer to start of treatment (in days), duration of first metastatic treatment (in days), prior use of systemic therapy in the first and second line metastatic settings (yes versus no), previous liver resection (yes versus no), rural residence (yes versus no), income quintile and Charlson's score (7 versus <7). Five strata based on quintiles of the propensity scores were used as an additional categorical covariate for adjustment in the model; stratification based on propensity score strata was also attempted but results obtained were very similar. The propensity score stratification balance within strata assessment was examined by two approaches: a two-way ANOVA method and standardized differences averaged over the strata. In the twoway ANOVA method (or logistic regression for binary covariates), each covariate was used as the dependent variable, whereas the independent variables included treatment, propensity score strata, and the interaction of treatment and propensity score strata. The test statistics for models with and without propensity score adjustment were then evaluated. Standardized differences are defined as the difference in means between the two treatment groups divided by standard deviation of the variable. 9 A standardized difference of >0.10 was considered as an indicator of imbalance. 9 To best estimate the treatment effect in our study, multivariable Cox and logistic regression models were adjusted by the propensity score strata and the above covariates. However, due to a large amount of missing data (with cancer stage at diagnosis accounting for about 17% of missing data points), only 74% (n 5 803) of data was analyzed in this complete case propensity score adjusted analysis. To further test for sensitivity and robustness of our data, we also performed multiple imputation assuming data were missing at random. An SAS default single Markov chain Monte Carlo method, which assumes multivariate normality, was used to generate five complete datasets. Results from the five full multivariable propensity score stratification models were combined to generate the inferences. All statistical analyses were performed using SAS version 9.4 and p values <0.05 were considered statistically significant.
Results
We identified 1081 patients who received at least 1 dose of either Cmab or Pmab for refractory KRAS wild-type mCRC in the Ontario drug database. Among them, 278 (25.7%) were treated with combination therapy (Cmab 1 I) and 803 (74.3%) received monotherapy with Pmab alone. Their mean age at first treatment was 63.2 6 11.8 and 48.1% were aged 65 and older. Over one-third (36.4%) of patients were What's new? Drugs targeting the epidermal growth factor receptor (EGFR) serve a critical role in the treatment of metastatic colorectal cancer (mCRC). Their effectiveness, however, is undermined by mutations in the KRAS oncogene. This study compared the effectiveness and toxicity of the EGFR-directed antibodies panitumumab, used alone, versus cetuximab, used in combination with irinotecan, in patients with refractory, nonmutated KRAS mCRC. Combination therapy yielded superior improvements in overall survival, warranting its consideration for use in irinotecan-tolerant mCRC patients. Measures of toxicity, including 14-day mortality and 30-day incidence of hospitalization, were similar in both groups, irrespective of age.
Cancer Therapy and Prevention female, 36.2% had rectal cancer and 60.1% were stage IV at presentation.
With the exception of age and duration of prior irinotecan use in the first line setting, baseline characteristics were balanced between patients treated with combination and monotherapy (Table 1) . Patients receiving combination therapy were younger at the time of treatment (mean 61.0 6 11.2 years) as compared to those receiving Pmab alone (mean 64.0 6 11.9 years), p < 0.01. Furthermore, patients receiving combination therapy remained on first line irinotecan-containing therapy longer than those treated with Pmab alone with a median (IQR) of 354 (182-573) versus 246 (127-448) days, p < 0.01. The proportion of patients treated with radiotherapy and liver resection were similar in both groups.
The use of Cmab 1 I as compared to Pmab alone was associated with a longer OS [median: 8.8 months vs 5.9 months] (Fig. 1) , with an adjusted HR of 0.62 [95% CI 0.53-0.73, p < 0.001] (Supporting Information II and III). Combination therapy was also associated with a prolonged TTD [median: 3.5 months vs 2.8 months] (Fig. 2) , with an adjusted HR of 0.61 [95%CI 0.52-0.72, p < 0.001] (Supporting Information IV). The OS among patients aged <65 was 8.9 months versus 5.7 months (p < 0.001) in favor of combination therapy with Cmab 1 I (Fig. S3a) . A similar OS benefit of Cmab 1 I was observed among older patients aged 65 and older (8.5 months versus 6.1 month, p 5 0.01) (Fig. S3b) . Benefits of combination versus monotherapy in the TTD outcome were also similar among older patients and their younger counterparts (Figs. S4a and S4b).
Both treatment regimens resulted in similar 14-day mortality and 30-day incidence of ED or hospital visits (Table 2a) . Thirtyday mortality was lower in the Cmab 1 I group, with an OR 0.41 (Tables 2a and 2b ). Interaction tests of treatment effect and age were >0.05 for all measured outcomes. Finally, when analyses were repeated using multiple imputation methods, similar results were obtained for all efficacy and toxicity endpoints (Supporting Information V).
Discussion
Our population-based study of 1,081 patients with refractory, KRAS exon 2 wild-type mCRC suggests a possible OS benefit with the combination of Cmab 1 I compared to Pmab alone without an associated increase in toxicity. The longer TTD in those who received combination therapy further support these results.
In addition, we demonstrate that patients aged 65 and older appear to experience similar benefit and toxicity from combination therapy as their younger counterparts. While awaiting randomized data, these results may form the bestavailable evidence to support the use of Cmab 1 I over monotherapy with Pmab for patients with RAS wild-type mCRC. The landmark trial of Cmab 6 I demonstrated improved tumor response rate (the primary efficacy endpoint) and time to progression with combination therapy, but OS was not significantly different. 6 A major limitation of this trial was that patients were not selected for KRAS status and, furthermore, the presence of cross-over may have hindered the detection of an OS benefit in favor of combination therapy. It is notable that the HR for TTD in our study [HR 0.61 (95% CI 0.52-0.72), p < 0.001] was comparable to the PFS in the BOND prospective trial [HR 0.54 (95% CI 0.42-0.71)]. 6 The median OS in our study [median: 8.8 months vs 5.9 months] was also similar to that of the BOND trial [median: 8.6 months vs 6.9 months], where outcomes were in favor of combination therapy. Indeed, results of well-constructed retrospective analyses have been shown to align with that of relevant prospective studies in the literature. [10] [11] [12] Only one retrospective study compared EGFR-directed antibody therapy (Pmab) alone or in combination with chemotherapy (Cmab 1 I). In this study of 178 patients in British Columbia, Canada, all of whom were KRAS exon 2 wildtype, the median OS favored combination therapy over monotherapy (8.3 vs 7.7 months) but this difference was not statistically significant [HR 1.29 (95% CI 0.77-2.14), p 5 0.34]. 13 TTD was not assessed and statistical power was very limited, with only 37 patients receiving combination therapy. 13 With a much larger sample size (n 5 1081), our study was better powered to detect an OS difference between combination and EGFR monotherapy.
In terms of toxicity, there was no difference in 14-day mortality, 30-day hospital, or ED visits (due to any cause) between Cmab 1 I and Pmab groups in our study. The higher 30-day mortality among young patients (age <65) receiving Pmab could possibly be explained by a lower threshold of physicians to administer an EGFR-antibody alone compared to combination treatment with cytotoxic chemotherapy at the end of life (Tables 2a and 2b ). This hypothesis would explain why 30-day mortality is higher among patients receiving Pmab monotherapy but the incidence of 30-day ED visits and 30-day hospitalization is similar in both groups. If this is the case, then 30-day mortality is not a true reflection of toxicity in this study. We also acknowledge that important but less severe toxicities that are not captured by short-term mortality or hospitalization were not assessed because such data were not available. Similarly, given the retrospective nature of this study, any difference in the severity or frequency of diarrhea was not captured.
Although the specific treatments compared in this analysis are most relevant to Canadian populations, the results may likely be generalized to reflect the effectiveness of either agent (Pmab or Cmab) alone or in combination with I. After all, Strengths of this study include a comprehensive Ontariowide population, with adjustment for the most important confounding variables. Furthermore, EGFR-directed antibody therapy is the final line of funded treatment in Ontario, limiting postprogression therapies. Limitations include the lack of randomization, evidence of selection of younger irinotecanresponsive patients for combination therapy, lack of information about performance status, and the use of KRAS exon 2 status (rather than extended RAS testing) to dictate eligibility for third line therapy. Hence, by including some patients with alternate RAS mutations, our study likely underestimates the difference between Pmab and Cmab 1 I in refractory mCRC. 14 In addition to exploring the effectiveness of EGFRantibodies in a "real world" setting, our study demonstrates similar benefit and toxicity in elderly patients (age 651) as in their younger counterparts. Given that elderly patients are often under-represented in clinical trials, high-quality observational data and use of registries is critical to inform the best treatment practice in our aging population. The ongoing ICREAM trial 15 is comparing Cmab 1 I versus Cmab alone prospectively, but given the small sample size of 101 patients and lack of long-term follow-up data, this retrospective data may represent the best-available evidence to inform treatment decisions for third line mCRC at this time.
In conclusion, "real world" data suggest a possible OS benefit with Cmab 1 I compared to Pmab alone even when adjusting for known confounders, without an associated increase in toxicity. Patients aged 65 and older appear to experience similar benefit and toxicity from combination therapy as compared to younger patients. These results suggest combination therapy may be the treatment of choice in fit irinotecan-tolerant patients. This is a complete case propensity score adjusted analysis. In the unadjusted model, the age interaction between treatment for 14 day mortality, 30 day mortality, hospital visits, and ED visits is p 5 0.033, 0.023, 0.21, and 0.53, respectively. In the adjusted model, the age interaction between treatment for 14 day mortality, 30 day mortality, hospital visits, and ED visits is p 5 0.39, 0.18, 0.48, and 0.97, respectively.
